Lipoprotein(a)

Lp(a) and Long-Term Cardiovascular Risk

April 24, 2024 Journal of the American College of Cardiology TAKE-HOME MESSAGE In a large pooled US cohort involving 27,756 individuals, higher lipoprotein(a) (Lp[a]) levels were significantly associated with an increased risk of atherosclerotic cardiovascular disease events over a mean follow-up period of 21.1 years, especially in those with Lp(a) levels in the highest percentile […]

Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk

August 19, 2020 JACC: Journal of the American College of Cardiology TAKE-HOME MESSAGE This study used data from 12,149 ARIC study participants to evaluate the relationship between two variables, elevated plasma Lp(a) and a family history (FHx) of coronary heart disease (CHD), and risk of atherosclerotic disease (ASCVD) and CHD over 21 years of follow-up. […]

Dietary natural products as emerging lipoprotein(a)-lowering agents

J Cell Physiol. 2019 Aug;234(8):12581-12594. doi: 10.1002/jcp.28134. Epub 2019 Jan 13. Dietary natural products as emerging lipoprotein(a)-lowering agents Amir Abbas Momtazi-Borojeni PMID: 30637725 DOI: 10.1002/jcp.28134 Abstract Elevated plasma lipoprotein(a) (Lp(a)) levels are associated with an increased risk of cardiovascular disease (CVD). Hitherto, niacin has been the drug of choice to reduce elevated Lp(a) levels in […]